Evidence map›Paper›PMID 28266652›Full record

ArticleScientific reports2017

Neoagaro-oligosaccharide monomers inhibit inflammation in LPS-stimulated macrophages through suppression of MAPK and NF-κB pathways.

Wei Wang, Pei Liu, Cui Hao, Lijuan Wu, Wenjin Wan, Xiangzhao Mao

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 100 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Wei WangCollege of Food Science and Engineering, and School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China.
Pei LiuCollege of Food Science and Engineering, and School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China.
Cui HaoInstitute of Cerebrovascular Diseases, Affiliated Hospital of Qingdao University Medical College, Qingdao, 266003, China.
Lijuan WuCollege of Food Science and Engineering, and School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China.
Wenjin WanDepartment of Biology, Hong Kong Baptist University, Hong Kong, China.
Xiangzhao MaoCollege of Food Science and Engineering, and School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China.
Ocean University of China · CNHong Kong Baptist University · HKQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoagaro-oligosaccharides derived from agarose have been demonstrated to possess a variety of biological activities, such as anti-bacteria and anti-oxidative activities. In this study, we mainly explored the inhibitory effects and the mechanisms of neoagaro-oligosaccharide monomers against LPS-induced inflammatory responses in mouse macrophage RAW264.7 cells. The results indicated that neoagaro-oligosaccharide monomers especially neoagarotetraose could significantly reduce the production and release of NO in LPS-induced macrophages. Neoagarotetraose significantly suppressed the expression and secretion of inducible nitric oxide synthase (iNOS) and proinflammatory cytokines such as TNF-α and IL-6. The inhibition mechanisms may be associated with the inhibition of the activation of p38MAPK, Ras/MEK/ERK and NF-κB signaling pathways. Thus, neoagarotetraose may attenuate the inflammatory responses through downregulating the MAPK and NF-κB signaling pathways in LPS-stimulated macrophages. In summary, the marine-derived neoagaro-oligosaccharide monomers merit further investigation as novel anti-inflammation agents in the future.

Indexed as

AnimalsAnti-Inflammatory AgentsCarbohydrate SequenceExtracellular Signal-Regulated MAP KinasesGalactosidesGene Expression RegulationInterleukin-6Interleukin-6 InhibitorsLipopolysaccharidesMAP Kinase Kinase KinasesMiceNF-kappa BNitric OxideNitric Oxide Synthase Type IIOligosaccharidesp38 Mitogen-Activated Protein KinasesAnti-Inflammatory AgentsExtracellular Signal-Regulated MAP KinasesGalactosidesIL6 protein, humanInterleukin-6Interleukin-6 InhibitorsLipopolysaccharidesMAP Kinase Kinase KinasesneoagarotetraoseNF-kappa BNitric OxideNitric Oxide Synthase Type IINos2 protein, mouseOligosaccharidesp38 Mitogen-Activated Protein Kinasesras ProteinsTumor Necrosis Factor-alpha

Identifiers

PMID28266652
PMCPMC5339798
OpenAlexW2592709671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.